estrogens, conjugated NDC 50742-391

NDC codes

FDA NDC Directory

Product NDC (as listed)50742-391Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50742-0391Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
50742-391-01	50742039101	100 TABLET, FILM COATED in 1 BOTTLE (50742-391-01)Marketed from Oct 16, 2025
50742-391-10	50742039110	1000 TABLET, FILM COATED in 1 BOTTLE (50742-391-10)Marketed from Oct 16, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): estrogens, conjugated
Generic name (nonproprietary): estrogens, conjugated
Active ingredients: Estrogens, Conjugated — 1.25 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Ingenus Pharmaceuticals, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 214023
Marketing start: Oct 16, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Estrogen Receptor Agonists (Mechanism)Conjugated (USP) (Chemical structure)
Identifiers: Product ID 50742-391_d18d3119-2cbe-4283-bb5a-891642a52629SPL ID d18d3119-2cbe-4283-bb5a-891642a52629SPL set ID 7277bab4-d8c2-4e4b-a0d9-5dfe1885d547RxCUI 197661, 197662UNII IU5QR144QX
Pharmacologic class: Estrogen

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N450742039101 followed by a unit qualifier and the quantity

Package 50742-0391-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 25, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Conjugated estrogens tablets is a mixture of estrogens indicated for: •Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause. ( 1.1 ) •Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause ( 1.2 ) •Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure ( 1.3 ) •Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease ( 1.4 ) •Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) ( 1.5 ) •Prevention of Postmenopausal Osteoporosis ( 1.6 ) 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate t…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 214023

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 214023
Product	Strength	Form · route	Labeler	Product NDC
estrogens, conjugated	Estrogens, Conjugated .9 mg/1	Tablet, Film coatedOral	Ingenus Pharmaceuticals, LLC	50742-390